NCT03019276 - A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Advanced Cancer

Interventions

DRUG

TQ-B3101

Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .

Trial Locations (1)

310016

RECRUITING

Sir Run Run Shaw Hospital,School of Medicine, Zhejiang University, Hangzhou